Laws and Labels: A Regulatory View of Biosimilars

Friday, October 30, 2015
Presented by: 
Erika Lietzan

Now that the first biosimilar product has been approved by FDA, healthcare professionals need to get up to speed on the evolving rules and policies that will separate biosimilars from interchangeable biologics and branded products. Join healthcare legal expert Erika Lietzan for a webinar examining the latest from the FDA on labeling biosimilars, the scientific and legal differences between biosimilars and other products, and the potential impact on prescribing and dispensing practices.

You may also like:

Blog Post

As 2017 comes to a close, the pace of change in the pharmacy sector continues to accelerate. As we reflect on the past year, several highlights warrant attention and indicate potential retail pharmacy trends to look for as we appr...

View Blog Post
Blog Post

The Society of Critical Care Medicine (SCCM) is committed to “Right Care, Right Now.” As part of this commitment, SCCM identifies patient care needs that require evidence-based best practice guidelines and works with expert...

View Blog Post
Blog Post

The emergency department provides opportunities to screen for opioid use disorder, provide interventions, and facilitate referral to ongoing treatment. Two published reports (from 2015 and 2017) out of Yale School of Medicine show...

View Blog Post

RxPerts Academy

Stay in the Know

Sign up to start receiving notifications via email of our upcoming webinars!

Sign Up